Convulsofin retard pills 300mg №100

Composition

Tablets of prolonged action, film-coated white, oblong, biconvex, with a risk on both sides, almost odorless.
1 tab.

sodium valproate - 199.8 mg

valproic acid — 87 mg, which corresponds to sodium valproate 100.2 mg

Excipients: hypromellose 2910 - 57 mg, hypromellose 2208 - 57 mg, colloidal silica water = 27 mg, acesulfame potassium - 3.6 mg.

The composition of the film coating: butyl methacrylate copolymer - 11.5 mg, Magnesium stearate - 2.89 mg, titanium dioxide - 1.97 mg, dibutyl sebacate - 1.75 mg, sodium lauryl sulfate - 0.84 mg.

Interaction

With the simultaneous use of Konvulsofina and hypnotic drugs, sedatives, neuroleptics, antidepressants and MAO inhibitors may increase their action. With the simultaneous use of Konvulsofina with other anticonvulsants (phenobarbital, phenytoin, carbamazepine), it is possible to increase the elimination of valproic acid from the body and decrease the activity of Konulsofin. With simultaneous use of Konvulsofina with hepatotoxic drugs and ethanol, the toxic effect of Konulsofin on the liver may be enhanced. With the simultaneous use of Konvulsofina and anticoagulants, incl. Acetylsalicylic acid, there is a mutual potentiation of the action on the blood coagulation system. With the simultaneous use of phenobarbital and primidone with Convulsofin there is an increase in the concentration of barbiturates in the blood plasma. With the simultaneous use of Konvulsofina and phenytoin may decrease the concentration of the latter in the blood plasma.

Active substance

Valproic acid

How to take, the course of administration and dosage

The initial dose of Konvulsofina is 5-10 mg / kg of body weight. Every 4-7 days, this dose is increased by 5 mg. The average daily dose for adults is 20 mg / kg of body weight, for children over 14 years old - 25 mg / kg of body weight, for children under the age of 14 years - 30 mg / kg of body weight. The daily dose is divided into 2-4 doses. In case of impaired renal function, the daily dose of Convulsofin should be reduced. The drug should be taken during or after a meal, without chewing and washing it down with a small amount of liquid.

Overdose

Symptoms: may increase the manifestations of the described side effects.

Side effects

On the part of the digestive system: possible nausea, vomiting, pain in the stomach, diarrhea (these phenomena can be eliminated by taking the drug after a meal and warned by prescribing it in gradually increasing doses), a transient increase in liver transaminase activity, increased salivation; rarely, marked impairment of the liver and pancreas (arising in the first 6 months of treatment, most often at 2-12 weeks and during the combined anti-epileptic therapy); in rare cases - stomatitis.
From the side of the central nervous system: feeling tired, tremor, paresthesia, ataxia, dizziness, headache; in some cases - drowsiness and impairment of consciousness up to a coma.
On the part of the blood coagulation system: thrombocytopenia, prolonged bleeding time.
Other: increase or decrease in body weight, increased appetite, alopecia, leukopenia, peripheral edema.

Indications

Generalized epileptic seizures in the form of absences, myoclonic seizures, tonic-clonic seizures; partial seizures; secondary generalized seizures.

Contraindications

Severe abnormal liver function; pronounced dysfunction of the pancreas; a medical lesion of the liver in history (including familial); hypersensitivity to valproic acid.

Special instructions

With extreme caution and under careful medical supervision, convulsofin should be prescribed to patients with congenital enzyme deficiency, with a history of bone marrow disorders, and blood clotting disorders, especially during combination antiepileptic therapy. The transition from treatment with another anticonvulsant to Convulsofin therapy is performed slowly, gradually lowering the dose of the previous drug. When prescribing Convulsofin simultaneously with other antiepileptic drugs, the dose of the latter, especially phenobarbital, should be reduced. Side effect occurs more often with combination therapy than with monotherapy with Convulsofin. If during the use of Konvulsofina there is an increase in epileptic seizures, indicating a decrease in the effectiveness of the drug, as well as an increase in the severity of side effects, a careful examination of the patient should be carried out with the definition of laboratory parameters of liver function, pancreas, blood coagulation system.If you identify significant violations Convulsofin should be canceled. Before surgical and dental manipulations, patients taking Convulsofin should determine the bleeding time. It should be borne in mind that while taking Convulsofin, false positive reactions to the presence of ketone bodies in the urine are possible.
Control of laboratory parameters. During therapy with Convulsofine, it is necessary to periodically monitor the activity of liver transaminases, the level of bilirubin, total protein, fibrinogen in the blood plasma, alpha-amylase in the urine, and thromboplastin time. In children, these figures should be determined before the start of treatment, then at short intervals (after 1, 3, 5, 7, 9 weeks) and then 1 time in 4 weeks until the end of the first 6 months of treatment; in adults and adolescents, before the start of treatment and every month during the first half of the treatment.
Use in pediatrics. With extreme caution and under careful medical supervision, Convulsofin should be prescribed to young children, especially during combination antiepileptic therapy. The risk of the development of pronounced liver dysfunction during the intake of Convulsofin is increased in infants and children under 1.5 years of age with severe epileptic seizures, especially if along with it there are brain damage, mental retardation and / or congenital metabolic disease. In this case, apply Convulsofin only for monotherapy. In children older than 10 years, the incidence of the hepatotoxic effect decreases significantly.
Influence on ability to drive motor transport and control mechanisms. The drug may impair the speed of psychomotor reactions and the ability to concentrate, so patients taking Convulsophine should refrain from potentially hazardous activities.

Pharmacy sales terms

On prescription

pharmachologic effect

Antiepileptic drug. The mechanism of action is associated with an increase in the content of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the CNS due to inhibition of the GABA transferase enzyme. This decreases the excitability and convulsive readiness of the motor areas of the brain.Konvulsofin inhibits the spread of epileptic excitation in the area of ​​cortical epileptogenic foci and increases the cortical convulsive threshold to electrical stimulation.